Plasma A- and B-type natriuretic peptides: Physiology, methodology and clinical use

Cardiovascular Research

Volumn 51, Issue 3, 2001, Pages 442-449

  Boomsma, Frans ^a,b   Van Den Meiracker, Anton H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Atrial function; Natriuretic peptide; Ventricular function

Indexed keywords

ANTHRACYCLINE; APROTININ; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CANDOXATRIL; CYCLIC GMP; HS 142 1; LISINOPRIL; LOSARTAN; NATRIURETIC PEPTIDE TYPE C; OMAPATRILAT;

AMINO TERMINAL SEQUENCE; BREAST CANCER; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; DRUG EFFECT; ENZYME BLOOD LEVEL; ENZYME STABILITY; GLOMERULUS FILTRATION RATE; HEART EJECTION FRACTION; HEART INFARCTION; HEART RIGHT VENTRICLE OVERLOAD; HUMAN; HYPERTENSION; LUNG EMBOLISM; METHODOLOGY; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS;

ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIURESIS; HUMANS; NATRIURETIC PEPTIDE, BRAIN;

EID: 0035882209     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(01)00195-X     Document Type: Review

References (110)

1. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rat
2. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
3. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure
4. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme
5. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans
6. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors
7. Expression of biologically active receptors for natriuretic peptides in the human uterus during pregnancy
8. Blood levels and renal effects of atrial natriuretic peptide in normal man
9. Brain natriuretic peptide administered to man: Actions and metabolism
10. Cardiovascular action of ANF: Contributions of renal, neurohumoral, and hemodynamic factors in sheep
11. Renal, endocrine and haemodynamic effects of human brain natriuretic peptide in normal man
12. Renal and systemic effects of synthetic atrial natriuretic factor
13. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct
14. Evidence for a proximal and distal nephron action of atrial natriuretic factor in man
15. Effect of atrial natriuretic factor (ANF) on blood pressure, renin and aldosterone in Goldblatt hypertension
16. Effect of physiological levels of atrial natriuretic peptide on hormone secretion: Inhibition of angiotensin-induced aldosterone secretion and renin release in normal man
17. Atriales natriuretisches peptid als angiotensin-II-antagonist
18. Antihypertensive effect of 5-day infusion of atrial natriuretic factor in humans
19. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in man
20. Modulation of exogenous and endogenous atrial natriuretic peptide by a receptor inhibitor
21. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors
22. Practical aspects of blood sampling for measurement of natriuretic peptides for assessing cardiac function
23. Cardiac peptides differ in their response to exercise: Implications for patients with heart failure in clinical practice
24. The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure
25. N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: Investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126)
26. Comparison of N-terminal pro-atrial natriuretic peptide and atrial natriuretic peptide in human plasma as measured with commercially available radioimmunoassay kits
27. A new, fast and reliable radioimmunoassay of brain natriuretic peptide in human plasma. Reference values in healthy subjects and in patients with different diseases
28. Analytical agreement and clinical correlates of plasma brain natriuretic peptide measured by three immunoassays in patients with heart failure
29. Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptide in human plasma
30. Development of a novel. N-Terminal-proBNP (NT-proBNP) assay with a low detection limit
31. An immunoluminometric assay for N-terminal pro-brain natriuretic peptide: Development of a test for left ventricular dysfunction
32. Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure
33. Stability of plasma atrial natriuretic peptide
34. Stability of human plasma atrial natriuretic peptide during storage at -80°C
35. Stabilization of human brain natriuretic peptide in blood samples
36. N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro
37. Stability of plasma concentrations of N and C terminal atrial natriuretic peptides at room temperature
38. Stability of plasma concentrations of N- and C-terminal atrial natriuretic peptides at room temperature
39. Prolonged stability of brain natriuretic peptide: Importance for non-invasive assessment of cardiac function in clinical practice
40. Stability of brain natriuretic peptide (BNP) in human blood samples
41. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: Implications for assessment of left ventricular dysfunction
42. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: Implications for clinical practice
43. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: An important prerequisite for its use as a biochemical parameter of atrial pressure in clinical routine
44. Plasma levels of atrial natriuretic factor in patients with congestive heart failure
45. Plasma atrial natriuretic peptide in cardiac disease and during infusion in healthy subjects
46. Atrial natriuretic peptide elevation in congestive heart failure in the human
47. Plasma levels and molecular forms of proatrial natriuretic peptides in healthy subjects and in patients with congestive heart failure
48. Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure
49. Relation of atrial natriuretic peptides to left ventricular systolic and diastolic function in heart failure
50. Neurohormonal activation at rest and at peak exercise in patients with congestive heart failure (NYHA class 1-3)
51. Comparison of plasma neurohormones in congestive heart failure patients with atrial fibrillation versus with sinus rhythm
52. Atrial fibrillation causes depletion of atrial natriuretic peptide in patients with advanced heart failure
53. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
54. BNP: Increasing importance in the pathophysiology and diagnosis of congestive heart failure
55. Brain and atrial natriuretic peptides at rest and at peak exercise in presymptomatic heart failure
56. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients
57. Towards a blood test for heart failure: The potential use of circulating natriuretic peptides
58. BNP: Soon to become a routine measure in the care of patients with heart failure?
59. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure
60. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure - Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
61. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure
62. N-terminal pro-BNP better predicts prognosis in patients presenting with heart failure for the first time than NT-pro-ANP or BNP
63. Measurement of neurohormones as prognostic markers for survival in patients with congestive heart failure
64. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy
65. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
66. Utility of B-natriuretic peptide (BNP) in the diagnosis of congestive heart in an urgent care setting
67. Plasma N-terminal atrial natriuretic peptide in acute myocardial infarction
68. N-terminal proatrial natriuretic factor; An independent predictor of long-term prognosis after myocardial infarction
69. Plasma brain natriuretic peptide as an indicator of left ventricular systolicfunction and long-term survival after acute myocardial infarction - Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide
70. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
71. Plasma levels of brain and atrial natriuretic peptides elevate in proportion to left ventricular end-systolic wall stress in patients with aortic stenosis
72. Plasma natriuretic peptides as indicators of left ventricular remodeling after myocardial infarction
73. Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction
74. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin - New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
75. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina
76. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: Correlation between plasma neurohormones and right ventricular dysfunction
77. Raised plasma BNP in a patient with acute pulmonary thromboembolism
78. The right ventricle in acute pulmonary embolism: Evaluation by plasma neurohormones
79. Natriuretic peptides in the human kidney
80. Plasma human brain natriuretic peptide in chronic renal failure
81. Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis
82. Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure
83. Prognostic significance of brain natriuretic peptide in haemodialysis patients
84. Renal function, neurohormonal activation, and survival in patients with chronic heart failure
85. Plasma brain natriuretic peptide and C-type natriuretic peptide in essential hypertension
86. Atrial and brain natriuretic peptides in cardiovascular disease
87. Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension
88. Relationship between left ventricular diastolic function and atrial natriuretic factor in never-treated mild hypertensives
89. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension
90. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy, changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor
91. Comparison of atrial natriuretic peptide. B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction
92. Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension
93. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP
94. Concentric but not eccentric left ventricular hypertrophy is associated with neurohumoral activation in elderly hypertensives
95. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension
96. Relationship between left ventricular geometry and brain natriuretic peptide levels in elderly subjects
97. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
98. Brain natriuretic peptide is a sensitive indicator of impaired left-ventricular function in elderly patients with cardiovascular disease
99. Biochemical detection of left-ventricular systolic dysfunction
100. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: Cross-sectional study
101. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population
102. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure - A double-blind, placebo-controlled, randomized crossover trial
103. Enhanced natriuretic response to neutral endopeptidase inhibition in heart-transplant recipients
104. Comparison of intravenous adrenomedullin with atrial natriuretic peptide in patients with congestive heart failure
105. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides
106. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
107. Blood pressure and neuroendocrine effects of angiotensin II receptor and beta-adrenoceptor antagonism in hypertension
108. Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones